DESCRIPTION

_Epilepsy & Behavior_ is the fastest-growing international journal uniquely devoted to the rapid dissemination of the most current information available on the behavioral aspects of seizures and epilepsy.

_Epilepsy & Behavior_ presents original peer-reviewed articles based on laboratory and clinical research. Topics are drawn from a variety of fields, including clinical neurology, neurosurgery, neuropsychiatry, neuropsychology, neurophysiology, neuropharmacology, and neuroimaging.

_Epilepsy & Behavior_ publishes papers on the study of:

- Localization of ictal and postictal behaviors
- Neuroendocrine aspects of epilepsy
- Psychiatric and psychosocial aspects of epilepsy
- Behavioral aspects of epilepsy surgery
- Cognitive and affective effects of seizure treatment
- Functional imaging
- Animal models

Letters to the Editor will only be considered if they comment on articles that were previously published in _Epilepsy & Behavior_. The journal does not publish Case Reports. Authors who submit these to _Epilepsy & Behavior_ will be offered a transfer or asked to resubmit their Case Reports to the journal’s companion title, _Epilepsy & Behavior Reports_.

Indexing

Cited in MEDLINE/PubMed and Index Medicus, Current Contents/Clinical Medicine, Science Citation Index-Expanded, NeuroScience Citation Index, PsychINFO, and EMBASE.

AUDIENCE

Researchers in neurology, neuropsychiatry, neuropsychology, neurophysiology, neuropharmacology, and neuroimaging, epilepsy fellows, epileptologists, neurologists, psychiatrists, neurosurgeons, and epilepsy nurses.
ABSTRACTING AND INDEXING

Scopus  
PsycINFO  
PubMed Central  
Google Scholar

EDITORIAL BOARD

Editor-in-Chief  
Marco Mula, St George's University Hospital and St George's University of London, London, United Kingdom  
Clinical epileptology, neuropsychiatry, clinical pharmacology

Associate Editors  
Robyn Busch, Cleveland Clinic, Cleveland, Ohio, United States of America  
Neuropsychology, Cognition, Memory, Mood, Epilepsy surgery  
Andrey Mazarati, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States of America  
Animal models of epilepsy, Post-traumatic epilepsy, Inflammation, Microbiome, Neurobehavioral comorbidities,  
Kette Valente, University of Sao Paulo Medical School, SÃO PAULO, Brazil  
Pediatrics, Genetics, Neurophysiology, Comorbidities, Child Neurology, Epilepsy

Cover Editor  
Steven Schachter, Massachusetts General Hospital Center for Integration of Medicine and Innovative Technology, Boston, Massachusetts, United States of America

Social Media & Web Editor  
Michael Owen Kinney, Belfast Health and Social Care Trust, Department of Neurology, Northern Ireland, United Kingdom

Social Media Intern  
Nathan Shlobin, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America

Book Review Editor  
Simon Shorvon, National Hospital for Neurology and Neurosurgery, London, United Kingdom  
Clinical epilepsy

Founding Editor-in-Chief  
Steven Schachter, Massachusetts General Hospital Center for Integration of Medicine and Innovative Technology, Boston, Massachusetts, United States of America

Founding Associate Editors  
Orrin Devinsky, New York University Grossman School of Medicine, New York, United States of America  
Christian Elger, University Hospital of Bonn, Department of Epileptology, Bonn, Germany

Past Associate Editor  
Bruce Hermann, University of Wisconsin-Madison, Department of Neurology, Madison, Wisconsin, United States of America

Editorial Board  
Hojjat Adeli, The Ohio State University, Department of Biomedical Informatics, Columbus, Ohio, United States of America  
Computational neuroscience, computational neurology, EEG-based diagnosis of neurological and psychiatric disorders including epilepsy, MCI, AD, ASD, PD, MDD, and ADHD  
Sarah Aminoff Kelley, Johns Hopkins University, Baltimore, Maryland, United States of America  
Eva Andermann, Montreal Neurological Institute-Hospital, Montréal, Quebec, Canada  
Miya Asato, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States of America  
Stephane Auvin, Robert-Debré Mother-Child University Hospital Biochemistry-Hormones Service, Paris, France  
Neurology, Epilepsy  
Jocelyn Bautista, Cleveland Clinic Neurological Institute, Cleveland, Ohio, United States of America
readmissions, healthcare utilization, PDSA cycle of improvement, quality metrics, PNES in adults, quality improvement, adult epilepsy, seizure semiology, video-EEG, familial epilepsy, genetic epidemiology

Ramon Bautista, University of North Florida, Jacksonville, Florida, United States of America
Sallie Ann Baxendale, University College London, London, United Kingdom
Memory, Cognitive Function, Neuropsychology, Epilepsy Surgery, Imaging
Selim Benbadis, Tampa General Hospital, Tampa, Florida, United States of America
Refractory seizures, EEG and EEG-video monitoring, Epilepsy surgery, Neurostimulation, Misdiagnosis and differential diagnosis of seizures, Psychogenic nonepileptic events
Sandro Beniczky, Aarhus University, Aarhus, Denmark
Source imaging, Epilepsy, Status epilepticus, Seizure detection, Wearable devices
Madison Berl, Children's National Medical Center, Washington, District of Columbia, United States of America
Frank Besag, Twinwoods Health Resource Centre, Bedford, United Kingdom
Mier Bialer, Hebrew University of Jerusalem, Jerusalem, Israel
Leonardo Bonilha, Medical University of South Carolina Comprehensive Epilepsy Center, Charleston, South Carolina, United States of America
Christian Brandt, Bethel Epilepsy Centre at Mara Hospital, Bielefeld, Germany
Clinical epileptology, intellectual disability, pharmacotherapy, comorbidities, genetics, developmental and epileptic encephalopathies
Francesco Brigo, Hospital Merano, Merano, Italy
Epilepsy
Martin Brodie, Western Infirmary, Glasgow, United Kingdom
Jorge Burneo, Western University, London, Ontario, Canada
Andrea Cavanna, University of Birmingham, Birmingham, United Kingdom
Jose Cavazos, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America
Zeina Chemali, Massachusetts General Hospital, Department of Psychiatry, Medford, Massachusetts, United States of America
Lei Chen, Sichuan University West China Hospital, Department of Neurology, Chengdu, China
clinical research from the fields of neurology, neurosurgery, neuropsychiatry, psychiatry, neurophysiology, neuroparmacology, and neuroimaging.
Richard Chin, The University of Edinburgh, Edinburgh, United Kingdom
Frank Drislane, Beth Israel Deaconess Medical Center, Department of Neurology, Boston, Massachusetts, United States of America
Status epilepticus, EEG monitoring, Refractory epilepsy
David Dunn, Indiana University School of Medicine, Indianapolis, Indiana, United States of America
Ozalp Ekinci, University of Health Sciences Turkey, Child and Adolescent Psychiatry Department, Istanbul, Turkey
Dario J Englot, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America
Surgery, Networks, Neuroimaging, Intracranial EEG, Neuromodulation
Peter Fisher, University of Liverpool, Liverpool, United Kingdom
Norberto Garcia-Cairasco, University of Sao Paulo, SAO PAULO, Brazil
Barry Gidal, University of Wisconsin-Madison, Madison, Wisconsin, United States of America
Pharmacokinetics, AED pharmacology, Adult Epilepsy
Anna Rita Giovagnoli, Foundation IRCCS Carlo Besta Neurological Institute, Milano, Italy
Cognitive and behavioral neurology, neuropsychology, psychotherapy
Arthur C. Grant, SUNY Downstate Health Sciences University, Department of Neurology, New York, New York, United States of America
Adult epilepsy, Clinical Neurophysiology, EEG, Medication adherence
Alla Guekht, Pirogov Russian National Research Medical University, Department of Neurology Neurosurgery and Medical Genetics, Moskva, Russian Federation
Cecil Hahn, The Hospital for Sick Children, Toronto, Ontario, Canada
Paediatric epilepsy, Neurocritical care, Critical care electroencephalography
Marla Hamberger, ColumbiaDoctors Neurology Comprehensive Epilepsy Center, New York, New York, United States of America
Lorie Harniwa, Seattle Children's Hospital, Seattle, Washington, United States of America
Sheryl Haut, Montefiore Medical Center, Bronx, New York, United States of America
Stephen Heinrichs, VA Boston Health Care System West Roxbury Campus, West Roxbury, Massachusetts, United States of America
Pharmacology
Christoph Helmstaedter, University of Bonn, Bonn, Germany
• Cognition, behaviour, personality, and psychosocial aspects in epilepsy• Cognitive and behavioural development in chronic and new onset epilepsies with current focus on limbic encephalitis
Neurobehavioral development and dementia  • Memory and executive functions  • Depression and organic brain syndrome (comorbidities)  • Hemisphere dominance and functional cerebral plasticity  • Behavioural assessment and test development  • Relevance of clinical measures for every day life (ecological validity)  • Outcome and quality control of epilepsy treatment: - Psychotropic effects of antiepileptic drugs incl. pharmaco-genetics - Short- and longer-term outcome of epilepsy surgery and brain stimulation procedures  • Psychological interventions and rehabilitative care in epilepsy patients

**Bruce Hermann**, University of Wisconsin-Madison, Department of Neurology, Madison, Wisconsin, United States of America

**Olivia Hogue**, Cleveland Clinic, Cleveland, Ohio, United States of America  
Translational science, Statistical methods, Study design

**Mau Sun Hua**, National Taiwan University, Taipei, Taiwan

**Yushi Inoue**, NHO Neurological Center Shizuoka Epilepsy, Shizuoka, Japan
Semiology, Treatment, Neuropsychology, Psychosocial issues

**Marilyn Jones-Gotman**, Université McGill, Montréal, Quebec, Canada

**Sung-Pa Park**, Kyungpook National University, Daegu, South Korea
Statistics, Analyses of neuroimaging data including PET, MRI, fMRI, DTI, EEG, MEG and optical imaging, Sparse clustering, Dimension reduction of high dimensional data, Survival and longitudinal data analysis

**Terence O’Brien**, The Royal Melbourne Hospital, Parkville, Australia

**W. Curt LaFrance, Jr.**, Brown University, Providence, Rhode Island, United States of America

**Angelo Labate**, Magna Graecia University of Catanzaro, Catanzaro, Italy
functional disorders, brain imaging, pathophysiology and treatment of pharmaco-resistant and pharmaco-responsive epilepsy, electro-clinical aspects of epilepsy

**Suncica Lah**, The University of Sydney, Sydney, New South Wales, Australia

**David Perez**, Massachusetts General Hospital, Department of Neurology, Boston, Massachusetts, United States of America
Neuroimaging, Neuropsychiatry, Functional [psychogenic nonepileptic / dissociative] seizures, Functional Neurological Disorder, Behavioral Neurology

**Kimford Jay Meador**, Stanford University School of Medicine, Stanford, California, United States of America

**Mohamed Mikati**, Duke University, Durham, North Carolina, United States of America

**Roberta Monterazzo Cysneiros**, Mackenzie Presbyterian University, SAO PAULO, Brazil

**Wenzhu Mowrey**, Albert Einstein College of Medicine, Bronx, New York, United States of America
Statistics, Analyses of neuroimaging data including PET, MRI, fmRI, DfI, EEG, MEG and optical imaging, Sparse clustering, Dimension reduction of high dimensional data, Survival and longitudinal data analysis

**Dorothée G.A. Kastelein-Nolst Trenité**, Utrecht University, Utrecht, Netherlands
Photosensitivity, Reflex epilepsy, Pharmacology

**Kenneth Kaufman**, Rutgers Robert Wood Johnson Medical School, Department of Psychiatry, Piscataway, New Jersey, United States of America

**Michael Kerr**, Cardiff University, Cardiff, Wales, United Kingdom

**Rosemary Kobau**, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

**Eric Kossoff**, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
epilepsy, ketogenic diet, children

**Angelo Labate**, Magna Graecia University of Catanzaro, Catanzaro, Italy
functional disorders, brain imaging, pathophysiology and treatment of pharmaco-resistant and pharmaco-responsive epilepsy, electro-clinical aspects of epilepsy

**Suncica Lah**, The University of Sydney, Sydney, New South Wales, Australia

**Epilepsy surgery, Pharmacology of epilepsy, Psychiatric aspect of epilepsy**

**Kenneth Kaufman**, Rutgers Robert Wood Johnson Medical School, Department of Psychiatry, Piscataway, New Jersey, United States of America

**Mau Sun Hua**, National Taiwan University, Taipei, Taiwan

**Yushi Inoue**, NHO Neurological Center Shizuoka Epilepsy, Shizuoka, Japan
Semiology, Treatment, Neuropsychology, Psychosocial issues

**Jana Jones**, University of Wisconsin-Madison, Madison, Wisconsin, United States of America

**Nigel Jones**, Monash University Central Clinical School, Melbourne, Australia
Animal modelling of epilepsy, Behavior, Pharmacology, EEG, Disease-modifying intervention, Neuroinflammation, Discovery Science Research

**Olivia Hogue**, Cleveland Clinic, Cleveland, Ohio, United States of America  
Translational science, Statistical methods, Study design

**Mau Sun Hua**, National Taiwan University, Taipei, Taiwan

**Yushi Inoue**, NHO Neurological Center Shizuoka Epilepsy, Shizuoka, Japan
Semiology, Treatment, Neuropsychology, Psychosocial issues

**Marilyn Jones-Gotman**, Université McGill, Montréal, Quebec, Canada

**Sung-Pa Park**, Kyungpook National University, Daegu, South Korea
Statistics, Analyses of neuroimaging data including PET, MRI, fMRI, DTI, EEG, MEG and optical imaging, Sparse clustering, Dimension reduction of high dimensional data, Survival and longitudinal data analysis

**Terence O’Brien**, The Royal Melbourne Hospital, Parkville, Australia

**W. Curt LaFrance, Jr.**, Brown University, Providence, Rhode Island, United States of America

**Angelo Labate**, Magna Graecia University of Catanzaro, Catanzaro, Italy
functional disorders, brain imaging, pathophysiology and treatment of pharmaco-resistant and pharmaco-responsive epilepsy, electro-clinical aspects of epilepsy

**Suncica Lah**, The University of Sydney, Sydney, New South Wales, Australia

**Cecilie Johannessen Landmark**, Oslo Metropolitan University, Faculty of Health Sciences, Oslo, Norway
Clinical pharmacology, Antiseizure medications, Adverse effects, Interaction, Therapeutic drug monitoring

**Jack Lin**, University of California Irvine, Irvine, California, United States of America

**Wolfgang Löschner**, University of Veterinary Medicine Hannover, Hannover, Germany
neuro, anticonvulsants

**Pavel Mares**, Czech Academy of Sciences, Praha, Czechia

**Carrie R. McDonald**, University of California San Diego, Department of Radiology, San Diego, California, United States of America

**Kimford Jay Meador**, Stanford University School of Medicine, Stanford, California, United States of America

**Mohamed Mikati**, Duke University, Durham, North Carolina, United States of America

**Roberta Monterazzo Cysneiros**, Mackenzie Presbyterian University, SAO PAULO, Brazil

**Wenzhu Mowrey**, Albert Einstein College of Medicine, Bronx, New York, United States of America
Statistics, Analyses of neuroimaging data including PET, MRI, fmRI, DfI, EEG, MEG and optical imaging, Sparse clustering, Dimension reduction of high dimensional data, Survival and longitudinal data analysis

**Colin Reilly**, University College London Institute of Child Health, London, United Kingdom

**Ronald Charles Reed**, West Virginia University, Morgantown, West Virginia, United States of America
Anti-seizure drug (ASD) pharmacokinetics, Photosensitivity in epilepsy, Anti-epileptic drug (AED) development clinical research, Epilepsy clinical therapeutics

**Ivan Rektor**, Masaryk University, Brno, Czechia
Epilepsy surgery, Neurostimulation and epilepsy, Epilepsy and cognitive networks
Markus Reuber, The University of Sheffield, Sheffield, United Kingdom
Patricia Rzezak, University of Sao Paulo Hospital of Clinics Institute of Psychiatry Laboratory of Clinical Neurophysiology, Sao Paulo, Brazil
Michael Saling, The University of Melbourne Melbourne School of Psychological Sciences, Melbourne, Australia
Jay Salpekar, Kennedy Krieger Institute, Baltimore, Maryland, United States of America
Rani Sarkis, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, United States of America
Michael Schoenberg, University of South Florida, Tampa, Florida, United States of America
 довольно, Neuropsychology, Memory, Outcome, Functional neuroanatomy, Deep brain stimulation
Hillary Shurtleff, Seattle Children's Center for Integrative Brain Research, Seattle, Washington, United States of America
Gagandeep Singh, Dayanand Medical College and Hospital, Ludhiana, India
Joseph I. Sirven, Mayo Clinic in Florida, Jacksonville, Florida, United States of America
Seizures, Epilepsy, Older Adults, Social Media, Outcomes, Public health, Education
Mary Lou Smith, University of Toronto Mississauga, Mississauga, Ontario, Canada
Kathy Speechley, Western University, London, Ontario, Canada
Carl Stafstrom, Johns Hopkins Medicine, Baltimore, Maryland, United States of America
Rainer Surges, University Hospital Bonn, Bonn, Germany
Jerzy P. Szaflarski *, UAB Epilepsy Center, Department of Neurology, Birmingham, Alabama, United States of America
Neuroimaging, Functional MRI, Functional seizures, Functional neurological disorders, PNES/ Psychogenic Non-Epileptic Seizures, Quality of life, Language
Michael Trimble, National Hospital for Neurology and Neurosurgery, London, United Kingdom
Vicente Villanueva, La Fe University and Polytechnic Hospital, Valencia, Spain
Antiepileptur medication, Epilepsy surgery, Video-EEG
Janelle L Wagner, Medical University of South Carolina College of Nursing, Charleston, South Carolina, United States of America
Elysa Widjaja, The Hospital for Sick Children, Toronto, Ontario, Canada
Samuel Wiebe, University of Calgary, Calgary, Alberta, Canada
Sarah Wilson, The University of Melbourne Asialink, Parkville, Australia
Elaine Wirrell, Mayo Foundation for Medical Education and Research, Rochester, Minnesota, United States of America
GUIDE FOR AUTHORS

INTRODUCTION

Epilepsy & Behavior has been, and still is, the fastest-growing international journal since its launch in 2000. Epilepsy & Behavior is uniquely devoted to the rapid dissemination of the most current information available on the behavioral aspects of seizures and epilepsy.

Epilepsy & Behavior presents original peer-reviewed articles based on laboratory and clinical research. Topics are drawn from a variety of fields, including clinical neurology, neurosurgery, neuropsychiatry, neuropsychology, neurophysiology, neuropharmacology, and neuroimaging.

Epilepsy & Behavior publishes papers on the study of:
- Localization of ictal and postictal behaviours
- Neuroendocrine aspects of epilepsy
- Psychiatric and psychosocial aspects of epilepsy
- Behavioral aspects of epilepsy surgery
- Cognitive and affective effects of seizure treatment
- Functional imaging
- Animal models

Types of article

Epilepsy & Behavior publishes the following types of articles:
- Original research articles (both clinical and laboratory research)
- Reviews
- Editorials
- Brief communications
- Letters
- Book reviews
- Calendar of events

Reviews: Please note that only unsolicited systematic reviews will be considered for publication. Authors are required to register the protocol for the systematic review before data extraction on an accessible, searchable site such as PROSPERO and include registration number.

Editorials: Please note that Editorials are only commissioned and they comment on articles published in Epilepsy & Behavior.

Letters: Please note that only letters to the Editor commenting on papers published in Epilepsy & Behavior will be considered for publication.

Contact details for submission

Authors should submit their articles electronically at: https://www.editorialmanager.com/EB/default.aspx.

Submission checklist

You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:
- E-mail address
- Full postal address

All necessary files have been uploaded:

Manuscript:
- Include keywords
- All figures (include relevant captions)
- All tables (including titles, description, footnotes)
- Ensure all figure and table citations in the text match the files provided
### Indicate clearly if color should be used for any figures in print

*Graphical Abstracts / Highlights files* (where applicable)

*Supplemental files* (where applicable)

### Further considerations

- Manuscript has been 'spell checked' and 'grammar checked'
- All references mentioned in the Reference List are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)
- A competing interests statement is provided, even if the authors have no competing interests to declare
- Journal policies detailed in this guide have been reviewed
- Referee suggestions and contact details provided, based on journal requirements

For further information, visit our [Support Center](https://www.elsevier.com/locate/yebeh).

---

### BEFORE YOU BEGIN

#### Ethics in publishing

Please see our information on [Ethics in publishing](https://www.elsevier.com/locate/yebeh).

#### Studies in humans and animals

If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The manuscript should be in line with the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms *sex* and *gender* should be used correctly.

Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

All animal experiments should comply with the [ARIVE guidelines](https://www.nc3rs.org.uk/ARIVE) and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National Research Council's Guide for the Care and Use of Laboratory Animals and the authors should clearly indicate in the manuscript that such guidelines have been followed. The sex of animals must be indicated, and where appropriate, the influence (or association) of sex on the results of the study.

#### Declaration of interest

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double anonymized) or the manuscript file (if single anonymized). If there are no interests to declare then please state this: 'Declarations of interest: none'. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. [More information](https://www.elsevier.com/locate/yebeh).

#### Declaration of generative AI in scientific writing

The below guidance only refers to the writing process, and not to the use of AI tools to analyse and draw insights from data as part of the research process.

Where authors use generative artificial intelligence (AI) and AI-assisted technologies in the writing process, authors should only use these technologies to improve readability and language. Applying the technology should be done with human oversight and control, and authors should carefully review and edit the result, as AI can generate authoritative-sounding output that can be incorrect, incomplete or biased. AI and AI-assisted technologies should not be listed as an author or co-author, or be cited as an author. Authorship implies responsibilities and tasks that can only be attributed to and performed by humans, as outlined in Elsevier’s [AI policy for authors](https://www.elsevier.com/locate/yebeh).
Authors should disclose in their manuscript the use of AI and AI-assisted technologies in the writing process by following the instructions below. A statement will appear in the published work. Please note that authors are ultimately responsible and accountable for the contents of the work.

**Disclosure instructions**
Authors must disclose the use of generative AI and AI-assisted technologies in the writing process by adding a statement at the end of their manuscript in the core manuscript file, before the References list. The statement should be placed in a new section entitled ‘Declaration of Generative AI and AI-assisted technologies in the writing process’.

**Statement:** During the preparation of this work the author(s) used [NAME TOOL / SERVICE] in order to [REASON]. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

This declaration does not apply to the use of basic tools for checking grammar, spelling, references etc. If there is nothing to disclose, there is no need to add a statement.

**Submission declaration and verification**
Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify compliance, your article may be checked by Crossref Similarity Check and other originality or duplicate checking software.

**Preprints**
Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy. Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple, redundant or concurrent publication' for more information).

**Use of inclusive language**
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. When coding terminology is used, we recommend to avoid offensive or exclusionary terms such as "master", "slave", "blacklist" and "whitelist". We suggest using alternatives that are more appropriate and (self-) explanatory such as "primary", "secondary", "blocklist" and "allowlist". These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

**Reporting sex- and gender-based analyses**

**Reporting guidance**
For research involving or pertaining to humans, animals or eukaryotic cells, investigators should integrate sex and gender-based analyses (SGBA) into their research design according to funder/sponsor requirements and best practices within a field. Authors should address the sex and/or gender dimensions of their research in their article. In cases where they cannot, they should discuss this as a limitation to their research's generalizability. Importantly, authors should explicitly state what definitions of sex and/or gender they are applying to enhance the precision, rigor and reproducibility of their research and to avoid ambiguity or conflation of terms and the constructs to which they refer (see Definitions section below). Authors can refer to the Sex and Gender Equity in Research (SAGER) guidelines and the SAGER guidelines checklist. These offer systematic approaches to the use and editorial review of sex and gender information in study design, data analysis, outcome reporting and research interpretation - however, please note there is no single, universally agreed-upon set of guidelines for defining sex and gender.
**Definitions**

Sex generally refers to a set of biological attributes that are associated with physical and physiological features (e.g., chromosomal genotype, hormonal levels, internal and external anatomy). A binary sex categorization (male/female) is usually designated at birth ("sex assigned at birth"), most often based solely on the visible external anatomy of a newborn. Gender generally refers to socially constructed roles, behaviors, and identities of women, men and gender-diverse people that occur in a historical and cultural context and may vary across societies and over time. Gender influences how people view themselves and each other, how they behave and interact and how power is distributed in society. Sex and gender are often incorrectly portrayed as binary (female/male or woman/man) and unchanging whereas these constructs actually exist along a spectrum and include additional sex categorizations and gender identities such as people who are intersex/have differences of sex development (DSD) or identify as non-binary. Moreover, the terms "sex" and "gender" can be ambiguous—thus it is important for authors to define the manner in which they are used. In addition to this definition guidance and the SAGER guidelines, the resources on this page offer further insight around sex and gender in research studies.

**Changes to authorship**

Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

**Article transfer service**

This journal uses the Elsevier Article Transfer Service to find the best home for your manuscript. This means that if an editor feels your manuscript is more suitable for an alternative journal, you might be asked to consider transferring the manuscript to such a journal. The recommendation might be provided by a Journal Editor, a dedicated Scientific Managing Editor, a tool assisted recommendation, or a combination. If you agree, your manuscript will be transferred, though you will have the opportunity to make changes to the manuscript before the submission is complete. Please note that your manuscript will be independently reviewed by the new journal. More information.

**Copyright**

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases.

For gold open access articles: Upon acceptance of an article, authors will be asked to complete a 'License Agreement' (more information). Permitted third party reuse of gold open access articles is determined by the author's choice of user license.

**Author rights**

As an author you (or your employer or institution) have certain rights to reuse your work. More information.
Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.

**Role of the funding source**
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement, it is recommended to state this.

**Open access**
Please visit our [Open Access page](https://www.elsevier.com/about/our-journals/open-access) for more information.

**Elsevier Researcher Academy**
Researcher Academy is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.

**Language (usage and editing services)**
Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's Author Services.

**Submission**
Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

**Submit your article**

**PREPARATION**

**Queries**
For questions about the editorial process (including the status of manuscripts under review) or for technical support on submissions, please visit our Support Center.

**Statistical analysis**

The authors should carefully consider proper statistical analysis, and are encouraged to consult with a biostatistician when they are not certain which statistical methods are to be used. The following components should be explicitly addressed in the Methods and applied to the data analysis.

Power analysis, to justify sample size. Test for normality, as well as an explanation as to whether the data are continuous or categorical, to justify the choice between parametric and non-parametric tests. Multivariate ANOVA when multiple dependent variables are involved Mixed models analysis of longitudinal data (unless repeated measures ANOVA is well justified)

If statistical methods are found to be inappropriate, the manuscript will be rejected with a possibility to resubmit once the corrections are made.

**Peer review**

This journal operates a single anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of one independent expert reviewer to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. Editors are not involved in decisions about papers which they have written themselves or have been written by family members or colleagues or which relate to products or services in which the editor has an
interest. Any such submission is subject to all of the journal's usual procedures, with peer review handled independently of the relevant editor and their research groups. More information on types of peer review.

**Use of word processing software**

It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

**Article structure**

**Subdivision - numbered sections**

Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

**Introduction**

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

**Material and methods**

Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

**Results**

Results should be clear and concise.

**Discussion**

The Discussion section should explore the significance of the results of the work, not repeat them. Results and Discussion should be separate and may be organized into subheadings. Avoid extensive citations and discussion of published literature.

**Conclusions**

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

**Essential title page information**

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lowercase superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.
• **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Please note that proprietary names for drugs should *not* be used in the article title.

**Highlights**

Highlights are optional yet highly encouraged for this journal, as they increase the discoverability of your article via search engines. They consist of a short collection of bullet points that capture the novel results of your research as well as new methods that were used during the study (if any). Please have a look at the example Highlights.

Highlights should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point).

**Abstract**

A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

**Graphical abstract**

Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view Example Graphical Abstracts on our information site.

Highlights are mandatory for Original Reports and Reviews only. They are optional but encouraged for all other article types.

**Keywords**

Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

**Abbreviations**

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

**Acknowledgements**

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

**Formatting of funding sources**

List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, it is recommended to include the following sentence:
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Units
Follow internationally accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.

Math formulae
Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

Artwork
Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Embed the used fonts if the application provides that option.
• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Provide captions to illustrations separately.
• Size the illustrations close to the desired dimensions of the published version.
• Submit each illustration as a separate file.
• Ensure that color images are accessible to all, including those with impaired color vision.

A detailed guide on electronic artwork is available.
You are urged to visit this site; some excerpts from the detailed information are given here.

Formats
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format. Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings, embed all used fonts.
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
• Supply files that are too low in resolution;
• Submit graphics that are disproportionately large for the content.

Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article. Please indicate your preference for color: in print or online only. Further information on the preparation of electronic artwork.
Color figures for exclusive use as **cover illustration** may be submitted by authors who are also submitting a manuscript for consideration. These figures should relate to the manuscript being submitted as well as the larger scope and focus of *Epilepsy & Behavior*.

**Figure captions**
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

**Tables**
Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

**References**

**Citation in text**
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either ‘Unpublished results’ or ‘Personal communication’. Citation of a reference as ‘in press’ implies that the item has been accepted for publication.

**Web references**
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

**Data references**
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

**Preprint references**
Where a preprint has subsequently become available as a peer-reviewed publication, the formal publication should be used as the reference. If there are preprints that are central to your work or that cover crucial developments in the topic, but are not yet formally published, these may be referenced. Preprints should be clearly marked as such, for example by including the word preprint, or the name of the preprint server, as part of the reference. The preprint DOI should also be provided.

**References in a special issue**
Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

**Reference management software**
Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles, such as Mendeley. Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal’s style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. More information on how to remove field codes from different reference management software.

**Reference style**
Text: Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.
List: Number the references (numbers in square brackets) in the list in the order in which they appear in the text.

Examples:
Reference to a journal publication:
Reference to a journal publication with an article number:
Reference to a book:
Reference to a chapter in an edited book:
Reference to a website:
Reference to a dataset:
Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors the first 6 should be listed followed by 'et al.' For further details you are referred to 'Uniform Requirements for Manuscripts submitted to Biomedical Journals' (J Am Med Assoc 1997;277:927–34) (see also Samples of Formatted References).

Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations.

Video
Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

Data visualization
Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions here to find out about available data visualization options and how to include them with your article.

Supplementary material
Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.
**Research data**

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings, which may also include software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the research data page.

**Data linking**

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the database linking page.

For supported data repositories a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

**Research Elements**

This journal enables you to publish research objects related to your original research – such as data, methods, protocols, software and hardware – as an additional paper in a Research Elements journal.

Research Elements is a suite of peer-reviewed, open access journals which make your research objects findable, accessible and reusable. Articles place research objects into context by providing detailed descriptions of objects and their application, and linking to the associated original research articles. Research Elements articles can be prepared by you, or by one of your collaborators.

During submission, you will be alerted to the opportunity to prepare and submit a manuscript to one of the Research Elements journals.

More information can be found on the Research Elements page.

**Data statement**

To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the Data Statement page.

**AFTER ACCEPTANCE**

**Online proof correction**

To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.
If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

**Offprints**

The corresponding author will, at no cost, receive a customized Share Link providing 50 days free access to the final published version of the article on ScienceDirect. The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Corresponding authors who have published their article gold open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

**AUTHOR INQUIRIES**

Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch. You can also check the status of your submitted article or find out when your accepted article will be published.

© Copyright 2018 Elsevier | https://www.elsevier.com